外周T／NK细胞淋巴瘤治疗的进展

Advance in treatment of the peripheral T-cell and natural killer/T-cell lymphoma

外周T细胞淋巴瘤（PTCL）是一组异质性非常明显的淋巴瘤，起源于成熟T淋巴细胞，对传统化疗反应不佳，大部分患者预后差。对复发难治患者的治疗选择尚未达成共识。目前正在进行一些新的临床试验，探讨一些新的治疗方法和药物，如第一次缓解后采用自体干细胞移植进行巩固治疗的前瞻性临床研究，以及denileukin diftitox或者CD52单抗（alemtuzumab）等靶向治疗药物与化疗的联合等。文章对外周T／NK细胞淋巴瘤的流行病学、预后因子和目前的治疗进行了探讨。

Peripheral T-cell lymphomas （PTCL） are a heterogeneous group of neoplasms, which originate from mature T-cells, with poor response to conventional chemotherapy and associated, in most cases, with a dismal prognosis. There has been no consensus on the best treatment strategy for patients with relapsed/ refractory disease. Attempts to adapt treatment regiments commonly used for B-cell lymphomas to PTCL have yielded disappointing results. A number of trials have been conducted to explore novel approaches, including prospective trials of consolidation therapy after first remission with autologous stem cell transplantation and the addition of agents such as denileukin diftitox or alemtuzumab to chemotherapy. This review aims to describe the epidemiology as well as the prognosis and current therapeutic strategies of the peripheral T-cell and natural killer/T-cell lymphoma.